Despite sound science, many recent drug launches are failing. The root cause is not the data but an underinvestment in market conditioning. Cautious investors and tighter budgets mean companies are starting their educational and scientific storytelling efforts too late, failing to prepare the market adequately.

The resurgence in biotech IPOs is marked by a significant shift towards selectivity. There have been zero preclinical IPOs this cycle, a stark contrast to the 19 that went public before the last peak, indicating investors now demand more mature assets with clinical data.

Allogene's stock fell after strong trial results, which its CMO attributes to market mechanics and investor confusion over its novel strategy, not the data itself. He claims direct investor feedback on the data was positive. This illustrates how complex clinical approaches can be misinterpreted by financial markets, decoupling stock performance from scientific success.

The reopening of the biotech IPO market is fragile. A key risk identified by investors is a series of failed IPOs, which could halt the sector's positive momentum. Consequently, there is intense pressure on bankers and VCs to exhibit "quality discipline," ensuring that only the most mature and high-potential companies go public first to build a track record of success.

Abivax's stock plummeted despite best-in-class efficacy for its ulcerative colitis drug. Investors fixated on a few cancer cases deemed unrelated to the treatment, showing extreme risk aversion to new biological pathways where long-term safety is uncertain.

The Phase 3 failure of Novartis's cardiovascular drug Pella Carson triggered a massive sell-off not just for Novartis, but also for competitors Amgen and Eli Lilly. This indicates investor fear that the entire LP(a) drug target class is flawed, rather than it being an issue with a single company's molecule.

Market dynamics, like investor fixation on AI or predatory short-selling, pose a greater risk to biotech firms than clinical trial results. A company can have a breakthrough drug but still fail if its stock—its funding currency—is ignored or attacked by Wall Street.

The successful, upsized IPOs of several biotechs suggest the market is receptive but cautious. Investors are prioritizing companies with lower-risk propositions, such as those building on validated biological mechanisms or advancing into late-stage trials, over purely speculative, early-stage science.

Despite positive sales figures, several biotech companies with recent product launches have seen flat or declining stock performance. This suggests investors either have overinflated expectations that even good numbers cannot meet, or they are simply not yet convinced by the long-term commercial stories.